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Abstract: Selective S1P1 receptor agonists have therapeutic potential to treat a variety of 
immune-mediated diseases. A series of 2-imino-thiazolidin-4-one derivatives displaying 
potent S1P1 receptor agonistic activity were selected to establish 3D-QSAR models using 
CoMFA  and  CoMSIA  methods.  Internal  and  external  cross-validation  techniques  were 
investigated as well as some measures including region focusing, progressive scrambling, 
bootstraping and leave-group-out. The satisfactory CoMFA model predicted a q
2 value of 
0.751 and an r
2 value of 0.973, indicating that electrostatic and steric properties play a 
significant role in potency. The best CoMSIA model, based on a combination of steric, 
electrostatic, hydrophobic and H-bond donor descriptors, predicted a q
2 value of 0.739 and 
an r
2 value of 0.923. The models were graphically interpreted using contour plots which 
gave more insight into the structural requirements for increasing the activity of a compound, 
providing a solid basis for future rational design of more active S1P1 receptor agonists. 
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1. Introduction 
Sphingosine-1-phosphate  (S1P),  a  widespread  lysophospholipid,  binds  five  specific  G-protein 
coupled  receptors  (S1P1-S1P5) [1–4]  and  exerts  a  variety  of  biological  activities  such  as  vascular 
maturation,  cell  survival,  proliferation,  differentitation,  migration  and  chemotaxis  [5–7].  The  S1P1 
receptor only couples to Gαi/o while the other S1P receptors are promiscuous with respect to G-protein 
coupling, activating G12/13 in addition to Gαi/o and also Gαq in the case of S1P2 and S1P3 [8]. S1P1 
modulates  egress  of  T-lymphocytes  from  thymus  and  peripheral  lymphoid  organs  [9],  and   
experiments  [10,11]  have  demonstrated  that  targeting  S1P1  is  sufficient  to  cause  lymphocyte 
sequestration to thymus and lymphoid organs, without affecting the innate immune system and even 
cellular  reactivity  of  lymphocytes  to  antigen  challenge.  On  the other  hand,  activation  of  the  S1P3   
does  not  relate  to  lymphocyte  recirculation  but  links  to  some  undesirable  effects  such  as 
bronchoconstriction, heart rate reduction and pulmonary epithelial  leakage [12–15]. Selective S1P1 
receptor agonists are promisingly developed as a novel immunomodulator. S1P1 receptor has been 
considered a potential target for a variety of immune-mediated diseases, including rheumatoid arthritis, 
psoriasis and multiple sclerosis disease. Recently, a novel class of S1P1 receptor agonists based on the 
2-imino-thiazolidin-4-one scaffold has been reported [8] and ligand-based drug design techniques will 
be employed to guide the synthesis of future generations of S1P1 receptor agonists since the crystal 
structure of S1P1 receptor remained unclear.   
Three-dimensional  quantitative  structure-activity  relationship  (3D-QSAR)  techniques  are  useful 
methods  of  ligand-based  drug  design  by  correlating  physicochemical  descriptors  from  a  set  of   
related  compounds  to their  known  molecular  activity  or  molecular  property  values  [16,17].  Many   
researchers  [18,19]  have  carried  out  quantitative  structure  activity  relationship  (QSAR)  studies  on 
thiazolidin-4-ones as anti-HIV agents, but the present work reports the first application of QSAR to 
study thiazolidin-4-ones as potent S1P1 receptor agonists [8]. We studied 61 2-imino-thiazolidin-4-one 
derivatives  using  comparative  molecular  field  analysis  (CoMFA)  [20]  and  comparative  molecular 
similarity indices analysis (CoMSIA) [21]. The satisfactory QSAR models obtained provide a solid 
basis for future rational design of more active and selective S1P1 receptor agonists within the family of 
S1P receptors. 
2. Results and Discussion 
2.1. CoMFA Analysis 
The most active molecule 60 was selected as the template for alignment (Figure 1) and the CoMFA 
model provided a cross-validation q
2 value of 0.751  with 5 components and an r
2 value of 0.973   
(Table 1). The activity values predicted for the tested compounds are in good agreement with the 
experimental values (Figure 2) and the r
2
pred value of 0.904 further confirms that the model is reliable 
and accurate with higher predictive capacity. The steric and electrostatic field contributions to the final Int. J. Mol. Sci. 2011, 12                         
 
6504
model were 54.5% and 45.5%, respectively. The results of the progressive scrambling showed that the 
value for the slope in the 5 component model is acceptable (Figure 3), and the optimum statistics are 
also seen for 5 components because cSDEP is at a minimum with Q
2 at a maximum (Table 2). 
Figure 1. Molecular alignment of 2-imino-thiazolidin-4-one derivatives. 
 
Table 1. Statistical results of CoMFA and the best CoMSIA models. 
  CoMFA  CoMSIA (Model 6) 
PLS statistics     
LOO cross q
2/SEP  0.751/0.320  0.739/0.328 
Group cross q
2/SEP  0.744/0.325  0.740/0.332 
Non-validated r
2/SEE  0.973/0.106  0.923/0.178 
F  250.674  84.398 
r
2
bootstrap  0.985 ± 0.006  0.973 ± 0.007 
Sbootstrap  0.074 ± 0.041  0.115 ± 0.064 
Optimal components  5  5 
Field distribution%     
Steric  54.5  12.5 
Electrostatic  45.5  29.0 
Hydrophobic    30.3 
H-bond donate    28.2 
r
2
pred  0.904  0.730 
Figure 2. Graph of experimental versus predicted pEC50 of the training set and the test set 
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Figure 3. Variation fitted curves for progressive scrambling analyses with random number 
seed: (left upper) 3 components; (right upper) 4 components; (left lower) 5 components; 
(right lower) 6 components. 
 
Table 2. Progressive scrambling results of the CoMFA model. 
Components  Q




3  0.403  0.531  1.391 
4  0.350  0.585  1.230 
5  0.540  0.542  1.021 
6  0.393  0.517  1.427 
7  0.433  0.583  1.391 
2.2. CoMSIA Analysis 
Eight  CoMSIA  models  were  generated  using  combinations  of  two,  three,  four,  and  all  five 
descriptors  as  shown  in  Table  3.  Model  6,  based  on  four  descriptors  of  steric,  electrostatic, 
hydrophobic and H-bond donor fields was found to be the most accurate yielding a q
2 value of 0.739 
and an r
2 value of 0.923. The Group cross q
2 value of 0.740, bootstrapped value of 0.973 ± 0.007 and 
test set r
2 value of 0.730 further approve that it is the best CoMSIA model. The predicted values are 
consistent with the experimental data (Figure 4). The steric field explains 12.5% of the variances, the 
electrostatic field explains 29.0%, the hydrophobic field for 30.3% and the hydrogen-bond donor for 
28.2% of the variance. Int. J. Mol. Sci. 2011, 12                         
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Table 3. Results of CoMSIA models using combinations of the four field descriptors. 












1  S and E  0.630/0.396  0.608/0.408  0.953 ± 0.011  0.129 ± 0.070  0.945/0.153 
2  S, E and H  0.735/0.310  0.723/0.324  0.873 ± 0.036  0.213 ± 0.127  0.871/0.221 
3  S, E and A  0.637/0.386  0.654/0.377  0.942 ± 0.017  0.152 ± 0.084  0.921/0.181 
4  S, E and D  0.695/0.359  0.692/0.361  0.952 ± 0.020  0.143 ± 0.090  0.929/0.173 
5  S, E, D and A  0.657/0.381  0.658/0.381  0.930 ± 0.021  0.175 ± 0.088  0.918/0.187 
6  S, E, D and H  0.739/0.328  0.740/0.332  0.973 ± 0.007  0.115 ± 0.064  0.923/0.178 
7  S, E, A and H  0.726/0.334  0.731/0.334  0.960 ± 0.011  0.139 ± 0.070  0.920/0.185 
8  S, E, D, A and H  0.719/0.340  0.709/0.351  0.953 ± 0.018  0.142 ± 0.077  0.910/0.192 
Figure 4. Graph of experimental versus predicted pEC50 of the training set and the test set 


























2.3. CoMFA Contour Maps 
The results of 3D-QSAR models are presented in the contour coefficient maps as shown in Figure 5. 
The CoMFA steric contour map of the most active compound 60 shows a large green polyhedron 
around 3, 4-positions of 5-benzylidene and a small green one locates near 2-position of N3-phenyl ring, 
suggesting that bulky substituents are preferred in these regions. Large yellow polyhedra at 2-position 
of  5-benzylidene  and  around  2-substituent  at  the  iminothiazolidinone  scaffold  indicate  that  bulks   
are  disfavored  here.  These  may  be  the  reason  why  compound  60  with  a  chlorine  atom  and  a 
hydroxylethyloxyl substitution at 3- and 4-positions of 5-benzylidene respectively,  a  methyl group 
linking to 2-position of 3-phenyl ring substituted at iminothiazolidinone ring, and no substitutions at 
2-position of 5-benzylidene ring, showed the most active. Similar to compound 60, compounds 58, 59, 
61  displayed  almost  identical  potency.  On  the  other  hand,  compound  56,  with  the  reverse  of 
substitution at each corresponding position, showed very low activity. The contour maps also show 
that compounds 18, 25–27, 40 exhibited much higher potency than 19, 30–32, 46 correspondingly.   
At the same time, the steric contour illustrated a weak trend for a reducing chain length to steadily   
improve the compound’s potency. For example, the activity of compounds 12, 11, 10, 9 was decreased 
in turn. Int. J. Mol. Sci. 2011, 12                         
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Figure 5. CoMFA field contour maps for active compound 60. Steric fields (Left): Green 
fields  indicate  steric  bulk  favored,  yellow  fields  indicate  steric  bulk  disfavored. 
Electrostatic fields (Right): Blue fields indicate electropositive groups favored, red fields 
indicate electronegative groups favored.   
   
For the electrostatic contour plots, two small blue polyhedra and a large red polyhedron are both 
located around the side chain linking to 4-position of 5-benzylidene, indicating that negatively charged 
groups  and  electron  donating  groups  are  both  available  in  these  regions.  A  large  red  polyhedron 
located at 3-position of 5- benzylidene and around 3, 4-positions of N3-phenyl ring, indicating that 
electron-withdrawing groups are preferred at these positions. That is why compounds 26–28 were 
shown  to  be  more  potent  than  compounds  29–32  with  electron-donating  groups,  and  compounds 
50–54  without  any  substituents  at  3-position  of  5-benzylidene  displayed  more  potency  than  the 
corresponding  compound  56.  Combined  with  its  steric  contour  map,  the  chloro-substituent  at 
3-position of the benzylidene ring is essential group for compound’s potency on S1P1.   
2.4. CoMSIA Contour Maps 
The best CoMSIA model contour maps of the most active analog (compound 60 in Table 4) are 
shown  in  Figure 6.  Its steric and electrostatic contour plots (Figure 6A,B) correlate well  with the 
CoMFA contour maps described above. Figure 6C displays the hydrophobic contour map represented 
by yellow and white polyhedra. A large yellow polyhedron and a small polyhedron located around 2, 3, 
4-positions of N3-phenyl ring respectively, indicating that hydrophobic substituents on ligands in these 
regions can be favored and the white ones disfavored such substituents. That is why compounds 58–61 
with a methyl group at the region showed far more potent than others. Figure 6D shows the CoMSIA 
hydrogen-bond donor fields denoted by cyan and purple contours. Cyan contours represent regions 
where  hydrogen-bond  donor  substituents  are  preferred  and  purple  contours  indicate  unfavorable 
regions. One large cyan contour around the side chain linking to 4-position of 5-benzylidene indicate 
that the free OH at 4-position or on its side chain is necessary for potencies. A large purple contour at 
2, 3-positions respectively shows where such substituents may be disfavored. That is why compound 
40 showed more potent than 41 while compound 56 was less active than compounds 50–54 and 57. Int. J. Mol. Sci. 2011, 12                         
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R1  R2  R3  R4  R5  Exp. 
CoMFA  CoMSIA 




phenyl  H  Cl  OH  7.208  7.188  0.020  7.129  0.079 
2 *  methyl  phenyl  H  Cl  OH  6.005  6.260  −0.255  6.280  −0.275 
3  ethyl  phenyl  H  Cl  OH  6.730  6.884  −0.154  6.921  −0.191 
4  n-propyl  phenyl  H  Cl  OH  7.174  7.149  0.025  7.107  0.067 
5  n-butyl  phenyl  H  Cl  OH  6.951  7.097  −0.146  7.143  −0.192 
6 *  isopropyl  phenyl  H  Cl  OH  7.328  7.078  0.250  7.267  0.061 
7  sec-butyl  phenyl  H  Cl  OH  6.992  6.900  0.092  6.951  0.041 
8  tert-butyl  phenyl  H  Cl  OH  6.833  6.887  −0.054  6.939  −0.106 
9  cyclopropyl  phenyl  H  Cl  OH  6.987  6.921  0.066  6.998  −0.011 
10  cyclobutyl  phenyl  H  Cl  OH  6.695  6.558  0.137  6.601  0.094 
11  cyclopentyl  phenyl  H  Cl  OH  6.460  6.548  −0.088  6.564  −0.104 
12 *  cyclohexyl  phenyl  H  Cl  OH  6.234  6.265  −0.031  6.260  −0.026 
13 *  isopropyl  isopropyl  H  Cl  OH  7.237  6.865  0.372  6.890  0.347 
14  isopropyl  n-hexyl  H  Cl  OH  6.550  6.555  −0.005  6.495  0.010 
15 *  isopropyl  cyclohexyl  H  Cl  OH  8.000  7.624  0.376  7.610  0.390 
16 *  isopropyl  ethoxycarbonylethyl  H  Cl  OH  6.320  6.405  −0.085  6.346  −0.026 
17 *  isopropyl  allyl  H  Cl  OH  7.259  7.185  0.074  7.177  0.082 
18  isopropyl  2-methylphenyl  H  Cl  OH  7.468  7.232  0.236  7.089  0.379 
19  isopropyl  3-methylphenyl  H  Cl  OH  6.959  6.947  0.012  6.997  −0.038 
20  isopropyl  4-methylphenyl  H  Cl  OH  7.108  7.021  0.087  7.025  0.083 
21  isopropyl  2,6-dimethylphenyl  H  Cl  OH  6.813  6.929  −0.116  6.987  −0.174 
22  isopropyl  2,3-dimethylphenyl  H  Cl  OH  7.143  7.321  −0.178  7.163  −0.020 
23 *  isopropyl  2,4-dimethylphenyl  H  Cl  OH  6.747  7.394  −0.647  7.202  −0.455 
24  isopropyl  2-ethylphenyl  H  Cl  OH  6.907  7.045  −0.138  7.226  −0.319 
25  isopropyl  2-chlorophenyl  H  Cl  OH  7.268  7.178  0.090  7.218  0.050 
26  isopropyl  3-chlorophenyl  H  Cl  OH  7.456  7.377  0.079  7.376  0.080 
27  isopropyl 
3-chloro-2-methylphe
nyl 
H  Cl  OH  7.509  7.399  0.110  7.472  0.037 
28  isopropyl 
3-chloro-4-methylphe
nyl 
H  Cl  OH  7.328  7.448  −0.120  7.481  −0.153 
29  isopropyl  2-methoxylphenyl  H  Cl  OH  6.975  6.933  0.042  7.019  −0.044 
30 *  isopropyl  3-methoxylphenyl  H  Cl  OH  6.587  7.015  −0.428  6.839  −0.252 
31  isopropyl  4-methoxylphenyl  H  Cl  OH  6.600  6.574  0.026  6.707  −0.107 
32 *  isopropyl  2,4-dimethoxyphenyl  H  Cl  OH  6.058  6.182  −0.124  6.321  −0.263 Int. J. Mol. Sci. 2011, 12                         
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Table 4. Cont. 
No  R1  R2  R3  R4  R5  Exp. 
CoMFA  CoMSIA 
Pred.  Res.  Pred.  Res. 
33 *  isopropyl  3-pyridyl  H  Cl  OH  6.449  6.613  −0.164  6.623  −0.174 
34  isopropyl  benzyl  H  Cl  OH  6.201  6.268  −0.067  6.195  0.006 
35  isopropyl  phenethyl  H  Cl  OH  6.034  6.077  −0.043  6.013  0.021 
36 *  isopropyl  4-phenylbutyl  H  Cl  OH  5.741  5.952  −0.211  6.053  −0.312 
37  isopropyl  phenyl  H  H  H  5.908  5.726  0.182  5.753  0.155 
38 *  isopropyl  phenyl  H  H  OH  6.914  6.653  0.261  6.794  0.120 
39  isopropyl  phenyl  H  F  OH  6.648  6.719  −0.071  6.726  −0.078 
40 *  isopropyl  phenyl  H  CH3  OH  7.432  7.674  −0.242  6.928  −0.496 
41  isopropyl  phenyl  H  OCH3  OH  6.699  6.654  0.045  6.597  0.102 
42  isopropyl  phenyl  H  H  OCH3  6.697  6.696  0.001  6.731  −0.034 
43  isopropyl  phenyl  H  OCH3  OCH3  6.650  6.739  −0.089  6.695  −0.045 
44  isopropyl  phenyl  H  H  NH(CH3)2  6.830  6.914  −0.084  6.669  0.161 
45  isopropyl  phenyl  H  H  Br  5.984  6.112  −0.128  5.829  0.155 
46 *  isopropyl  phenyl  H  OCH3  H  6.733  6.521  0.212  6.299  0.434 
47 *  isopropyl  phenyl  H  OH  H  6.124  6.008  0.116  6.087  0.037 
48  isopropyl  phenyl  H  OH  OCH3  6.353  6.283  0.070  6.471  −0.118 
49  isopropyl  phenyl  CH3  H  H  5.190  5.196  −0.006  5.609  −0.419 
50  isopropyl  phenyl  H  H  CH2OH  6.389  6.433  −0.044  6.233  0.156 
51 *  isopropyl  phenyl  H  H  (CH2)2OH  6.991  6.572  0.419  6.431  0.560 
52 *  isopropyl  phenyl  H  H  (CH2)3OH  7.009  6.848  0.162  6.975  0.034 
53  isopropyl  phenyl  H  H  O(CH2)2OH  7.022  7.031  −0.009  6.905  0.117 
54 *  isopropyl  phenyl  H  H 
O(CH2)3 
OH 
7.237  6.979  0.258  6.859  0.378 
55 *  isopropyl  phenyl  H  H 
OCH 
(CH2OH)2 
5.064  5.607  −0.543  5.438  −0.374 
56  isopropyl  phenyl  H  O(CH2)2OH  H  5.850  5.762  0.088  5.815  0.035 
57  isopropyl  phenyl  H  H 
O(CH2)3N 
(CH3)2 
6.465  6.512  −0.047  6.535  −0.070 
58  n-propyl  2-methylphenyl  H  Cl  OH  7.721  7.538  0.183  7.279  0.442 
59  n-propyl  2-methylphenyl  H  Cl 
O(CH2)2 
OH 
7.959  7.933  0.026  8.154  −0.195 




8.041  8.026  0.015  8.031  0.010 




8.013  8.061  −0.048  7.907  0.106 
* Test set. Int. J. Mol. Sci. 2011, 12                         
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Figure  6.  CoMSIA  fields.  The  CoMSIA  fields  from  model  6  are  shown  with  active 
compound 60. (A) Steric fields, green indicates steric bulk favored, yellow indicates bulk 
disfavored; (B) Electrostatic fields, blue indicates electropositive groups favored, red fields 
indicate electronegative groups favored; (C) Hydrophobic fields, yellow indicates favored, 
gray disfavored; (D) H-bond donor field, cyan indicates donor favored, purple disfavored.   
 
3. Materials and Methods 
3.1. Data Set 
Sixty-one compounds in the present study were taken from the published works of Martin H. Bolli 
and co-workers [8], and some molecules whose activity was shown not to be very exact from the 
experimental study were excluded. The structures of the molecules and their biological data are given 
in Table 4. For convenience, the EC50 values of S1P1 receptor agonists were often converted to their 
negative logarithm (pEC50) values. The pEC50 values of these compounds have a span of 3.0 log 
units  from  5.06  to  8.04,  providing  a  broad  and  homogenous  data  set  for  3D-QSAR  study  [22].   
20  compounds  were  randomly  selected  as  the  test  set  based  on  the  structural  diversity  while  the 
remaining 41 compounds were taken as the training set.   
Three-dimensional  structure  building  and  all  modeling  were  performed  using  the  SYBYL  8.1 
program package of Tripos, Inc. 3D structures of all compounds were constructed using the Sketch 
Molecule module. Structural energy minimization was carried out using the standard Tripos molecular 
mechanics force field and Gasteiger–Hückle charge, with the convergence criterion set at 0.05 kcal/(Å mol) 
and the max iterations for the minimization set to 2000. 
One method of 3D-QSAR optimization is known as region focusing [23]. However, application of 
region focusing in this study resulted in a little decrease from 0.751 to 0.739 for the internal validity 
and from 0.973 to 0.958 for the non-validated r
2. Obviously, the region focusing is not essential in this 
CoMFA model. Int. J. Mol. Sci. 2011, 12                         
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3.2. Molecular Alignment 
A good alignment is the most important element for CoMFA and CoMSIA analysis although probe 
atom type, lattice shifting step size and over all orientation of the aligned compounds may have a 
bearing on their results [24]. The quality and the predictive ability of the model are directly dependent 
on the alignment rules. Once the active conformation was determined by energy minimization using 
Powell method and Tripos standard force field [25] with a distance-dependent dielectric function, the 
alignment was performed based on some rules such as substructure overlap, pharmacophore overlap 
and  docking  [26].  In order to  produce  a  more  robust  CoMFA  and  CoMSIA  models  with  a  good 
cross-validated r
2 value, the 5-benzylidenylthizaolindin-4-one with structural rigidity was selected as 
the common substructure to overlap and to align all of the molecules and the most active compound 65 
was used as the alignment template. Alignment of all compounds was shown in Figure 1. It can be 
seen that all the compounds studied have similar active conformations. 
3.3. Partial Least Squares (PLS) Analysis 
PLS  analysis  [27],  used  to  linearly  correlate  the  3D-QSAR  fields  to  biological  activity  values,   
was  first  carried  out  by  the  leave-one-out  (LOO)  and  leave-group-out  (10  compound  groups) 
cross-validation  methods, respectively,  to  determine  cross-validated  r
2 (q
2)  values  and  the optimal 
number of components, in which one compound was removed from the data set and its activity was 
predicted using the model from the rest of the data set. Non-cross-validation was then performed to 
establish the final 3D-QSAR model using the optimal number of components, in which conventional 
correlation coefficient (r
2), standard errors of estimate (SEE), and F ratio between the variances of 
calculated and observed activities were given. 
The optimal number of components, usually corresponding to the highest cross-validated squared 
coefficient (q
2), was selected on the basis of the lowest standard error of prediction (SEP) and avoiding 
over-fitting the models. A higher component was accepted and used only when the q
2 differences 
between two components was larger than 10%. The q
2 has been a good indicator of the accuracy of 
actual predictions. In general, q
2 values can be separated into three categories: q
2 > 0.6 means a fairly 
good model, q
2 = 0.4 – 0.6 means a questionable model, and q
2 < 0.4 a poor model [27]. To further 
assess  the  robustness  of  the  derived  models,  bootstraping  analysis  (10  runs)  was  also  utilized  to 
calculate confidence intervals for the r
2 and SEE [28,29].   
3.4. CoMFA Studies 
Three-dimensional grid spacing was set at 2 Å in the x, y, and z directions and a 3D cubic lattice 
consisted  its  grid  region  that  extended  at  least 4  Å  beyond  van  der  Waals  volume  of  all  aligned 
molecules in all directions. Steric energy (Lennard-Jones potential) and electrostatic energy (Coulomb 
potential) were calculated using the Tripos force field for each molecule, and the sp
3-hybrized carbon 
atom with a +1 charge was taken as the probe atom to determine the magnitude of the field values. All 
energies that exceeded the cutoff value of 30 kcal/mol were ignored for the reduction of domination by 
large steric and electrostatic energies. With standard options for scaling of variables, the regression 
analysis was carried out using partial least squares (PLS) method [27]. To improve the signal to noise Int. J. Mol. Sci. 2011, 12                         
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ratio, the column filtering was set to 2.0 kcal/mol, then those lattice points whose energy variation was 
below  this  threshold  were  automatically  omitted  [30].  The  final  model  was  developed  with  the 
optimum  number  of  components  to  yield  a  non  cross-validated  r
2  value.  Despite  being  unable  to 
describe all of the binding forces, CoMFA is still a widely useful tool for QSAR analysis at 3D level.   
3.5. CoMSIA Studies 
CoMSIA is similar to CoMFA based on the same assumption that changes in binding affinities of 
ligands are related to changes in molecular properties represented by fields. Moreover, for CoMSIA, 
besides steric and electrostatic fields, three other different fields (hydrophobic, hydrogen bond donor, 
and hydrogen bond acceptor) are calculated [31]. A Gaussian function was introduced to determine the 
distance  between  the  probe  atom  and  the  molecule  atoms.  Similarity  indices  inside  and  outside 
different molecular surfaces can be calculated at all grid points, however only outside indices were 
calculated in CoMFA. Equation used to calculate the similarity indices is as follows: 
2
, ( ) ,
iq r q
F K j probe k ik
i
A W W e
  
 
Where, A is the similarity index at grid point q, summed over all atoms i of the molecule j under 
investigation. Wprobe, k is the probe atom with radius 1 Å, charge +1, hydrophobicity +1, hydrogen bond 
donating +1 and hydrogen bond accepting +1. Wik is the actual value of the physicochemical property 
k of atom i. riq is the mutual distance between the probe atom at grid point q and atom i of the test 
molecule. α is the attenuation factor whose optimal value is normally between 0.2 and 0.4, with a 
default value of 0.3 [32,33]. 
3.6. Sensitivity of a PLS Model 
Most members of the data set, especially for large data sets, may have “twins” which make a near 
twin of each left-out molecule likely remain in the training data and usually obtain good predictions, so 
the q
2 statistic obtained from cross-validation may give a false sense of confidence [34]. Progressive 
scrambling is used to test the model’s stability by determining the sensitivity of a QSAR model to 
small  systematic  perturbations  of  the  response  variable  [35,36].  The  values  of  Q




yy’  are  used  to  interpret  the  predictivity  of  the  model  without  the  potentially  confusing 
redundancy, in which the Q
2 statistic is an estimate of the predictivity of the model after removing the 
effects  of  redundancy,  and  the  cSDEP  statistic  is  an  estimated  cross-validated  standard  error  at a 





yy’ means slope of q
2 evaluated at the specified critical point 
with respect to r
2
yy’. 
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Here, y’ indicates the perturbed (scrambled) responses and the statistic r
2
yy’ expresses the degree of 
correlation between the perturbed responses and the original ones. The Q
2 statistic obtained in this way 
is  very  conservative,  in  that  it  is  necessarily  reduced  by  the  level  of  noise  introduced to  remove 




yy’ means what extent the model changes with small changes to the dependent variable. In a 
stable model, changing proportionally with small changes in underlying data, has a slope near unity 
while  unstable  models  change  greatly  with  small  changes  in  underlying  response  values  and   
its  effective  slope  is  generally  greater than  1.2.  This  method  was  employed  to  verify  the  optimal 
number of components and test the cross-validation against the possibility of such a redundancy in our   
training set [37]. 
3.7. Predictive Correlation Coefficient 
q
2 is a useful but not sufficient criterion for model validation, so an external test set (r
2
pred) [38] was 
claimed for the estimation of predictive ability. Equation of predictive values r
2
pred is as follows: 
2 1 ( / ) pred r PRESS SD    
Therein, SD means the sum of squared differences between the measured activities of the test set 
and the average measured activity of the training set. 
4. Conclusions 
Although  many  researchers  have  carried  out  quantitative  structure  activity  relationship  (QSAR) 
studies  on  thiazolidin-4-one  as  anti-HIV  agents,  the  present  work  reports  the  first  application  of   
QSAR  to  study  thiazolidin-4-ones  as  potent  S1P1  receptor  agonists  [8].  We  studied  61 
2-imino-thiazolidin-4-one derivatives using CoMFA and CoMSIA,  and  some predictive 3D-QSAR 
models have been developed. Both CoMFA and CoMSIA models provided good statistical results in 
terms  of  q
2  and  r
2  values,  suggesting  the  significant  correlations  of  molecular  structures  with  its 
biological activities. Compared with CoMFA, CoMSIA provided a slightly better statistical model. 
The final CoMSIA model was generated from steric, electrostatic, hydrophobic and hydrogen-bond 
donor fields and validated by a variety of methods including crossvalidation, non-crossvalidation and 
test set predictions. The model developed has high internal validity (q
2 above 0.6) and high predictive 
ability (test set r
2 above 0.7). Compared with SAR summarized by Martin H. Bolli, the results of 
3D-QSAR models presented in the contour coefficient maps further revealed how steric, electrostatic, 
hydrophobic and hydrogen-bond donor modifications should significantly affect the bioactivities of 
these compounds. Thus, the results of the quantitative structure activity relationships (QSAR) studies 
gave  an  insight  to  design  new  S1P1  receptor  agonists  which  can  effectively  treat  a  variety  of 
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